Literature DB >> 16601336

Successful treatment of extremely severe fetal anemia due to anti-Jra alloimmunization.

Yuki Ishihara1, Shigeki Miyata, Yoshihide Chiba, Takeshi Kawai.   

Abstract

BACKGROUND: Although Jr(a) hemolytic disease of the newborn (HDN) is generally considered to be mild, we encountered a case of anti-Jr(a) alloimmunization hydrops fetalis due to extremely severe fetal anemia that required aggressive intrauterine treatment. CASE REPORT: A Japanese woman developed hydrops fetalis at the 29th week of gestation. Blood examination was highly positive for anti-Jr(a) antibodies. Cordocentesis demonstrated that the fetus had anti-Jr(a) antibodies and the lowest fetal hemoglobin concentration was 2.3 g/dl. After a total of four intravascular transfusions, fetal hydrops improved and a healthy girl of 2,120 g was delivered at the 35th week of gestation. The initial neonatal hemoglobin concentration at birth was 7.2 g/dl. After two straight transfusions, the infant's anemia did not worsen. Anti-Jr(a) antibodies became negative without developing hyperbilirubinemia.
CONCLUSION: The incidence of Jr(a) negativity can lead to underestimation of the risk of Jr(a) alloimmunization. This case shows that anti-Jr(a) alloimmunization may cause HDN and hydrops fetalis. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601336     DOI: 10.1159/000091354

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  2 in total

1.  Successful Management of the Fetal Severe Anemia Associated with Jra Alloimmunization by Intrauterine Transfusion of Jr(a+) Red Blood Cells.

Authors:  Masatake Toshimitsu; Shinichi Nagaoka; Shuusaku Kobori; Yuichiro Takahashi; Jun Murotsuki
Journal:  Case Rep Obstet Gynecol       Date:  2019-02-24

2.  Suspected anemia caused by maternal anti-Jra antibodies: a case report.

Authors:  Yasufumi Endo; Shoichi Ito; Yoshiko Ogiyama
Journal:  Biomark Res       Date:  2015-08-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.